Ratings Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			Pre-market 09:18:32 am
7.47 ^USD	-1.32%		7.53	+0.80%

Apr. 16	Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	MT
Apr. 16	Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
RECURSION PHARMACEUTICALS, INC.	-24.24%	1.76B	B-
VERTEX PHARMACEUTICALS INCORPORATED	-3.39%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+2.61%	96.84B	B+
ARGENX SE	-0.96%	21.48B	B
BIONTECH SE	-18.14%	20.82B	B+
GENMAB A/S	-7.56%	18.6B	A-
WUXI APPTEC CO., LTD.	-40.70%	16.81B	A-
BEIGENE, LTD.	-26.89%	13.78B	B
NEUROCRINE BIOSCIENCES, INC.	+1.12%	13.4B	C+
SAREPTA THERAPEUTICS, INC.	+22.25%	11.06B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes